Latest in Sales Climb

Sort by

376 items

Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales

US group revises down upper end of full-year revenue estimates
Business - Financial Times - October 30
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Business - MarketWatch - October 30
Prada continues to defy luxury slowdown as Miu Miu sales boom

Italian group bucks gloom but warns that conditions in Asia are becoming ‘more challenging’
Business - Financial Times - October 30

Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales